Dr. Sandeep Singhal Joins BioMark Scientific Advisory Team

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Return to homepage

(TheNewswire)



October 2, 2018 / TheNewswire / Vancouver, British Columbia – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that it has appointed Dr. Sandeep Singhal to its scientific advisory team.

Rashid Ahmed, President and CEO, says, “We are delighted to welcome Dr. Singhal into our scientific advisory team. He provides expertise in clinical trial design, deep analytical data support and integration. His experience is vitally important in validating, improving robustness of our assay(s) and integrating a multi perspective of Omics as a clinical diagnostic tool. His capabilities to develop and implement custom bioinformatics programming solutions in collaboration with labs will be an important asset for BioMark. Dr. Singhal’s contributions will enhance our analytical bench strength as we commence commercialization of our assays which is powered by genomics, metabolomics and big data”.

Leveraging big data from genomics, proteomics and metabolomics (Omics) and incorporating smarter analytics to BioMark’s technology platform will improve the overall performance of the tests significantly. Offering a unified view of these disciplines will lead to better diagnostics tools available to better manage cancer treatment at large says”, Dr. Singhal.

About Dr. Sandeep Singhal

Dr. Singhal has over 14 years of experience as a Bioinformatician in India, Belgium, USA and Canada with a strong background in cancer genomics, omic-data integration, modeling, algorithm development, statistical analysis and application implementation. He has published extensively in leading scientific journals such as Nature Genetics, Journal of Clinical Oncology, EMNO molecular medicine. He is an editorial board member of Journal of Current Trends in Translational and Research. Dr Singhal holds Ph.D. in Bioinformatics, from Jules Bordet Institute, Universite libre de Bruxelles (ULB) Bruxelles, Belgium and is currently a Research Scientist at Columbia University, New York where his research focus is to understand the role of metabolism and transcriptional cross talk between epigenetic co-regulators and hormones receptor-mediated signalling pathways in both enhancer function and promoter targeted mechanism of gene control.

Dr. Singhal completed his postdoctoral fellowship at Department of Biomedical Informatics, University of Pittsburgh, & The Hamner Institutes for Health Sciences, North Carolina, USA and University of Alberta Canada.

About BioMark Diagnostics Inc.

BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors.

Further information about BioMark is available under its profile on the SEDAR website www.sedar.com and on the CSE website https://thecse.com/.

For further information on BioMark, please Contact:

Rashid Ahmed Bux

President & CEO

BioMark Diagnostics Inc.

Tel. 604-370-0779

Email: [email protected]  

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of Biomark.  Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The CSE has not reviewed, approved or disapproved the content of this press release.

Copyright (c) 2018 TheNewswire - All rights reserved.